search
Back to results

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 (TRuE-CHE1)

Primary Purpose

Hand Eczema

Status
Withdrawn
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Ruxolitinib cream
Vehicle
Sponsored by
Incyte Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hand Eczema focused on measuring eczema, chronic hand eczema (CHE), dermatitis, skin disease, JAK inhibitor

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of chromic hand eczema (CHE) as defined by hand eczema (HE) lasting > 3 months or ≥ 2 flares within the previous 12 months.
  • Screening and baseline IGA-CHE 3 or 4.
  • Baseline CHE-related Itch NRS ≥ 4.
  • Recent history (within the past 1 year of baseline) of inadequate response to treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), or oral alitretinoin; or intolerance or contraindication to TCS or TCI or oral alitretinoin.
  • Willingness to avoid pregnancy or fathering children based on the criteria below.

Exclusion Criteria:

  • Known triggers for CHE (allergic or irritant, such as those identified by previous patch tests) cannot be avoided during the course of this study.
  • Participants who have an unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to baseline.
  • Participants with concurrent conditions and history of other diseases such as other active skin disease or infection on the hands; immunocompromised; chronic or acute infection requiring systemic treatments; active acute skin infection; other concomitant skin conditions that may interfere with study assessments or compromise participant safety; other types of eczema; chronic asthma requiring high dose of inhaled corticosteroids; current or history of hepatitis B or C virus infection.
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Laboratory values outside of the protocol-defined criteria.
  • Use of protocol-defined treatments within the indicated washout period before baseline.
  • Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks before baseline.
  • Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.
  • Further exclusion criteria apply.

Sites / Locations

  • Southwest Skin Specialists Phoenix Biltmore
  • Raoof Md Encino
  • First Oc Dermatology
  • Marvel Clinical Research Llc
  • Well Pharma Medical Research Corporation
  • Psoriasis Treatment Center of South Florida
  • Lenus Research Medical Group, Llc
  • Delricht Research
  • Arlington Dermatology
  • Midwest Allergy Sinus Asthma, Sc
  • Dermatologist Specialist
  • Grafton Dermatology and Cosmetic Surgery
  • Delricht Research
  • Washington University
  • Jubilee Clinical Research Inc
  • Juva Skin and Laser Center
  • Oregon Medical Research Center
  • Oregon Health & Science University
  • Clinical Neuroscience Solutions Cns Healthcare Memphis Research Center
  • International Clinical Research Tennessee Llc
  • Austin Institute For Clinical Research Aicr Pflugerville
  • Progressive Clinical Research
  • Center For Clinical Studies Webster
  • University of Utah
  • West End Dermatology Associates
  • Dermatology Specialists of Spokane
  • Dermatology Research Institute Inc.
  • Care Clinic
  • Cca Medical Research
  • Lynderm Research Inc
  • Fakultni Nemocnice U Sv. Anny V Brne
  • Ccr Ostrava S.R.O.
  • Ccr Czech A.S.
  • Clintrial S.R.O.
  • Krajska Zdravotni A.S. - Masarykova Nemocnice V Usti Nad Labem O.Z.
  • Klinikum Der Johann Wolfgang Goethe-Universitaet
  • Derma-Study-Center Friedrichshafen Gmbh
  • Dermatologikum Hamburg Gemeinschaftspraxis Gbr
  • Universitaetsklinikum Schleswig-Holstein
  • Praxis Dr. Beate Schwarz
  • Beldio Research Gmbh
  • Klifos - Klinische Forschung Osnabruck
  • Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp. Z O.O.
  • Etg Warszawa
  • Hospital General Universitario de Alicante
  • Hospital de La Santa Creu I Sant Pau
  • Hospital General Universitario Gregorio Maranon
  • Hospital de Manises
  • Hospital Universitario Quironsalud Madrid

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Ruxolitinib

Vehicle

Arm Description

Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.

Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.

Outcomes

Primary Outcome Measures

Proportion of participants achieving Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS)
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

Secondary Outcome Measures

Proportion of participants with a ≥ 4-point improvement in chronic hand eczema (CHE) related Itch NRS score
The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable) on a daily basis.
Proportion of participants with a ≥ 2-point improvement in CHE-related Pain NRS score
The Pain NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable).
Change from baseline in the modified Total Lesion Symptom Score (mTLSS)
The mTLSS is a validated tool for assessing hand eczema. The scale quantifies the 7 features (erythema, scaling, hyperkeratosis/lichenification, vesiculation, oedema, fissures, and pruritus/pain) of HE (0 = none, 1 = mild, 2 = moderate, and 3 = severe).
Proportion of participants achieving an IGA-CHE-TS from baseline
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.
Change from baseline in CHE-related Itch Numerical Rating Scale (NRS) score (weekly average)
The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable).
Change from baseline in CHE-related Pain NRS score (weekly average)
The Pain NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable).
Time to ≥ 4-point improvement from baseline in CHE-related Itch NRS score
The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable) on a daily basis.
Time to ≥ 2-point improvement from baseline in CHE-related Pain NRS score.
The Pain NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable) on a daily basis.
Percentage change in Hand Eczema Severity Index (HECSI)
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales.
Proportion of Participants with HECSI-75
HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales.
Proportion of participants with HECSI-90
HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales.
Mean Patient Global Impression of Change (PGIC) score
The Patient Global Impression of Change (PGIC)is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.
Proportion of participants with each score on the PGIC
The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.
Proportion of Participants with a score of either 1 or 2 on the PGIC
The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.

Full Information

First Posted
January 21, 2022
Last Updated
November 14, 2022
Sponsor
Incyte Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT05219864
Brief Title
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1
Acronym
TRuE-CHE1
Official Title
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 (TRuE-CHE1): A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Business decision; no safety concerns.
Study Start Date
January 31, 2023 (Anticipated)
Primary Completion Date
April 25, 2024 (Anticipated)
Study Completion Date
September 22, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Incyte Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hand Eczema
Keywords
eczema, chronic hand eczema (CHE), dermatitis, skin disease, JAK inhibitor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Participants will receive ruxolitinib cream (1.5%) or vehicle cream for 16 weeks, after which they will be offered the opportunity to receive ruxilitinib cream (1.5%) in the open-label treatment extension period for another 16 weeks.
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ruxolitinib
Arm Type
Experimental
Arm Description
Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.
Arm Title
Vehicle
Arm Type
Placebo Comparator
Arm Description
Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.
Intervention Type
Drug
Intervention Name(s)
Ruxolitinib cream
Other Intervention Name(s)
INCB18424 cream
Intervention Description
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Intervention Type
Drug
Intervention Name(s)
Vehicle
Intervention Description
Vehicle cream is a topical formulation applied as a thin film to affected areas.
Primary Outcome Measure Information:
Title
Proportion of participants achieving Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS)
Description
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.
Time Frame
Week 16
Secondary Outcome Measure Information:
Title
Proportion of participants with a ≥ 4-point improvement in chronic hand eczema (CHE) related Itch NRS score
Description
The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable) on a daily basis.
Time Frame
Week 16
Title
Proportion of participants with a ≥ 2-point improvement in CHE-related Pain NRS score
Description
The Pain NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable).
Time Frame
Week 16
Title
Change from baseline in the modified Total Lesion Symptom Score (mTLSS)
Description
The mTLSS is a validated tool for assessing hand eczema. The scale quantifies the 7 features (erythema, scaling, hyperkeratosis/lichenification, vesiculation, oedema, fissures, and pruritus/pain) of HE (0 = none, 1 = mild, 2 = moderate, and 3 = severe).
Time Frame
Up to Week 32
Title
Proportion of participants achieving an IGA-CHE-TS from baseline
Description
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.
Time Frame
Up to Week 32
Title
Change from baseline in CHE-related Itch Numerical Rating Scale (NRS) score (weekly average)
Description
The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable).
Time Frame
Up to Week 32
Title
Change from baseline in CHE-related Pain NRS score (weekly average)
Description
The Pain NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable).
Time Frame
Up to Week 32
Title
Time to ≥ 4-point improvement from baseline in CHE-related Itch NRS score
Description
The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable) on a daily basis.
Time Frame
Up to Week 32
Title
Time to ≥ 2-point improvement from baseline in CHE-related Pain NRS score.
Description
The Pain NRS is a validated, self-reported, instrument for measurement of itch intensity and subject will rate the intensity of their pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable) on a daily basis.
Time Frame
Up to Week 32
Title
Percentage change in Hand Eczema Severity Index (HECSI)
Description
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales.
Time Frame
Week 16
Title
Proportion of Participants with HECSI-75
Description
HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales.
Time Frame
Weeks 2, 8, 16 and 32
Title
Proportion of participants with HECSI-90
Description
HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales.
Time Frame
Weeks 2, 8, 16, and 32
Title
Mean Patient Global Impression of Change (PGIC) score
Description
The Patient Global Impression of Change (PGIC)is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.
Time Frame
Up to Week 32
Title
Proportion of participants with each score on the PGIC
Description
The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.
Time Frame
Up to Week 32
Title
Proportion of Participants with a score of either 1 or 2 on the PGIC
Description
The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.
Time Frame
Up to Week 32

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of chromic hand eczema (CHE) as defined by hand eczema (HE) lasting > 3 months or ≥ 2 flares within the previous 12 months. Screening and baseline IGA-CHE 3 or 4. Baseline CHE-related Itch NRS ≥ 4. Recent history (within the past 1 year of baseline) of inadequate response to treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), or oral alitretinoin; or intolerance or contraindication to TCS or TCI or oral alitretinoin. Willingness to avoid pregnancy or fathering children based on the criteria below. Exclusion Criteria: Known triggers for CHE (allergic or irritant, such as those identified by previous patch tests) cannot be avoided during the course of this study. Participants who have an unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to baseline. Participants with concurrent conditions and history of other diseases such as other active skin disease or infection on the hands; immunocompromised; chronic or acute infection requiring systemic treatments; active acute skin infection; other concomitant skin conditions that may interfere with study assessments or compromise participant safety; other types of eczema; chronic asthma requiring high dose of inhaled corticosteroids; current or history of hepatitis B or C virus infection. Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data. Laboratory values outside of the protocol-defined criteria. Use of protocol-defined treatments within the indicated washout period before baseline. Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks before baseline. Pregnant or lactating participants, or those considering pregnancy during the period of their study participation. Further exclusion criteria apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Haq Nawaz, MD
Organizational Affiliation
Incyte Corporation
Official's Role
Study Director
Facility Information:
Facility Name
Southwest Skin Specialists Phoenix Biltmore
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85018
Country
United States
Facility Name
Raoof Md Encino
City
Encino
State/Province
California
ZIP/Postal Code
91436
Country
United States
Facility Name
First Oc Dermatology
City
Fountain Valley
State/Province
California
ZIP/Postal Code
92708
Country
United States
Facility Name
Marvel Clinical Research Llc
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92647
Country
United States
Facility Name
Well Pharma Medical Research Corporation
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
Facility Name
Psoriasis Treatment Center of South Florida
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33028
Country
United States
Facility Name
Lenus Research Medical Group, Llc
City
Sweetwater
State/Province
Florida
ZIP/Postal Code
33172
Country
United States
Facility Name
Delricht Research
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
Arlington Dermatology
City
Rolling Meadows
State/Province
Illinois
ZIP/Postal Code
60008
Country
United States
Facility Name
Midwest Allergy Sinus Asthma, Sc
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62604
Country
United States
Facility Name
Dermatologist Specialist
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40241
Country
United States
Facility Name
Grafton Dermatology and Cosmetic Surgery
City
Houma
State/Province
Louisiana
ZIP/Postal Code
70364
Country
United States
Facility Name
Delricht Research
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70115
Country
United States
Facility Name
Washington University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Jubilee Clinical Research Inc
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89106
Country
United States
Facility Name
Juva Skin and Laser Center
City
New York
State/Province
New York
ZIP/Postal Code
10022
Country
United States
Facility Name
Oregon Medical Research Center
City
Portland
State/Province
Oregon
ZIP/Postal Code
97223
Country
United States
Facility Name
Oregon Health & Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Clinical Neuroscience Solutions Cns Healthcare Memphis Research Center
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
Facility Name
International Clinical Research Tennessee Llc
City
Murfreesboro
State/Province
Tennessee
ZIP/Postal Code
37130
Country
United States
Facility Name
Austin Institute For Clinical Research Aicr Pflugerville
City
Houston
State/Province
Texas
ZIP/Postal Code
77056
Country
United States
Facility Name
Progressive Clinical Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78213
Country
United States
Facility Name
Center For Clinical Studies Webster
City
Webster
State/Province
Texas
ZIP/Postal Code
77598
Country
United States
Facility Name
University of Utah
City
Murray
State/Province
Utah
ZIP/Postal Code
84107
Country
United States
Facility Name
West End Dermatology Associates
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23233
Country
United States
Facility Name
Dermatology Specialists of Spokane
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202
Country
United States
Facility Name
Dermatology Research Institute Inc.
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2J 7E1
Country
Canada
Facility Name
Care Clinic
City
Red Deer
State/Province
Alberta
ZIP/Postal Code
T4P-1K4
Country
Canada
Facility Name
Cca Medical Research
City
Ajax
State/Province
Ontario
ZIP/Postal Code
L1S 7K8
Country
Canada
Facility Name
Lynderm Research Inc
City
Markham
State/Province
Ontario
ZIP/Postal Code
L3P 1X3
Country
Canada
Facility Name
Fakultni Nemocnice U Sv. Anny V Brne
City
Brno
ZIP/Postal Code
656 91
Country
Czechia
Facility Name
Ccr Ostrava S.R.O.
City
Ostrava
ZIP/Postal Code
702 00
Country
Czechia
Facility Name
Ccr Czech A.S.
City
Pardubice
ZIP/Postal Code
53000
Country
Czechia
Facility Name
Clintrial S.R.O.
City
Praha 10
ZIP/Postal Code
100 00
Country
Czechia
Facility Name
Krajska Zdravotni A.S. - Masarykova Nemocnice V Usti Nad Labem O.Z.
City
Usti Nad Labem
ZIP/Postal Code
401 13
Country
Czechia
Facility Name
Klinikum Der Johann Wolfgang Goethe-Universitaet
City
Frankfurt
ZIP/Postal Code
60590
Country
Germany
Facility Name
Derma-Study-Center Friedrichshafen Gmbh
City
Friedrichshafen
ZIP/Postal Code
88045
Country
Germany
Facility Name
Dermatologikum Hamburg Gemeinschaftspraxis Gbr
City
Hamburg
ZIP/Postal Code
20354
Country
Germany
Facility Name
Universitaetsklinikum Schleswig-Holstein
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Facility Name
Praxis Dr. Beate Schwarz
City
Langenau
ZIP/Postal Code
89129
Country
Germany
Facility Name
Beldio Research Gmbh
City
Memmingen
ZIP/Postal Code
87700
Country
Germany
Facility Name
Klifos - Klinische Forschung Osnabruck
City
Osnabruck
ZIP/Postal Code
49074
Country
Germany
Facility Name
Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp. Z O.O.
City
Elblag
ZIP/Postal Code
82-300
Country
Poland
Facility Name
Etg Warszawa
City
Warszawa
ZIP/Postal Code
02-793
Country
Poland
Facility Name
Hospital General Universitario de Alicante
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Facility Name
Hospital de La Santa Creu I Sant Pau
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Facility Name
Hospital General Universitario Gregorio Maranon
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Hospital de Manises
City
Manises
ZIP/Postal Code
46940
Country
Spain
Facility Name
Hospital Universitario Quironsalud Madrid
City
Pozuelo de Alarcon
ZIP/Postal Code
28223
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

We'll reach out to this number within 24 hrs